Pamela Stephenson
Corporate Officer/Principal en DISC MEDICINE, INC. .
Fortuna: 2 M $ al 31/03/2024
Perfil
Pamela Stephenson is currently the Chief Commercial Officer at Disc Medicine, Inc. Her former positions include being an Independent Director at Zynerba Pharmaceuticals, Inc. from 2019 to 2023, and Vice President-Global Market Access & Value at Vertex Pharmaceuticals, Inc. from 2008 to 2019.
She also served as the Chief Commercial Officer at Albireo Pharma, Inc. Ms. Stephenson received her undergraduate degree from Brown University and her graduate degree from Boston University School of Public Health.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
DISC MEDICINE, INC.
0.15% | 26/02/2024 | 36 666 ( 0.15% ) | 2 M $ | 31/03/2024 |
Cargos activos de Pamela Stephenson
| Empresas | Cargo | Inicio |
|---|---|---|
| DISC MEDICINE, INC. | Corporate Officer/Principal | 26/02/2024 |
Antiguos cargos conocidos de Pamela Stephenson.
| Empresas | Cargo | Fin |
|---|---|---|
| ZYNERBA PHARMACEUTICALS, INC. | Director/Board Member | 10/10/2023 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01/03/2019 |
| ALBIREO PHARMA, INC. | Corporate Officer/Principal | - |
Formación de Pamela Stephenson.
| Brown University | Undergraduate Degree |
| Boston University School of Public Health | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| ZYNERBA PHARMACEUTICALS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
| Disc Medicine, Inc. |
- Bolsa de valores
- Insiders
- Pamela Stephenson
